What is Celcuity?
Headquartered in Minneapolis, Celcuity operates at the intersection of therapeutic development and companion diagnostics. The company distinguishes itself through the CELsignia platform, which utilizes live patient tumor cells to identify specific patient populations that may derive clinical benefit from existing targeted therapies. By in-licensing and developing therapies that align with these diagnostic insights, Celcuity effectively bridges the gap between traditional oncology treatments and personalized medicine. This integrated strategy positions the firm as a critical player in the biotechnology sector, specifically within the high-growth market of cancer diagnostics and targeted therapeutics.
How much funding has Celcuity raised?
Celcuity has raised a total of $117.5M across 6 funding rounds:
Multiple Rounds
$31.1M
Debt
$350K
Stock Offering
$24M
Debt
$62M
Debt (2017): $5.8M, investors not publicly disclosed
Debt (2017): $2.6M, investors not publicly disclosed
Stock Issuance/Offering (2017): $22.8M, investors not publicly disclosed
Debt (2020): $350K featuring PPP
Stock Issuance/Offering (2021): $24M backed by Craig-Hallum Capital Group
Debt (2024): $62M with participation from Oxford Finance
Key Investors in Celcuity
Oxford Finance
Oxford Finance is a specialty finance firm that provides flexible capital solutions tailored to the unique needs of healthcare and life sciences companies.
Craig-Hallum Capital Group
Craig-Hallum Capital Group is an investment banking firm focused on providing capital markets expertise and strategic advisory services to growth-oriented companies.
PPP
Public-Private Partnership
What's next for Celcuity?
With the recent influx of capital, Celcuity is well-positioned to accelerate its clinical development pipeline and expand the utility of its CELsignia diagnostic technology. The strategic focus will likely center on deepening its therapeutic portfolio and strengthening its market presence as it moves toward later-stage clinical trials. As the company continues to refine its diagnostic capabilities, investors will be closely monitoring the efficacy of its targeted therapies and the potential for broader adoption of its companion diagnostic platform across the oncology landscape. The firm's ability to leverage this financing will be pivotal in its transition toward commercial-stage operations and long-term value creation in the competitive biotech arena.
See full Celcuity company page
